Literature DB >> 23502451

Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis.

Zhao Limei1, Chen Yong, Xu Yan, Tang Shuai, Xie Jiangyan, Liang Zhiqing.   

Abstract

OBJECTIVE: A meta-analysis was performed to estimate the diagnostic accuracy of positron emission tomography/computed tomography (PET/CT) in suspected recurrent ovarian cancer.
MATERIALS AND METHODS: PubMed, The Cochrane Library, Embase, and Web of Science were systematically searched. Studies that compared PET/CT and reference standards within patients for diagnosis of suspected recurrent ovarian cancer were included.
RESULTS: Twenty-nine studies involving 1651 patients with ovarian cancer were analyzed. For recurrent versus nonrecurrent ovarian cancer, the pooled sensitivity, specificity, positive likelihood (LH) ratio, negative LH ratio, and diagnostic odds ratio of ovarian carcinoma were 88.6% (95% confidence interval [CI], 86.6%-90.3%), 90.3% (95% CI, 87.6%-92.7%), 6.104 (95% CI, 3.904-9.543), 0.122 (95% CI, 0.077%-0.192%), and 57.032 (95% CI, 30.764-105.73), respectively, for recurrence in the PET/CT. Because sensitivity, specificity, positive LH ratio, and negative LH ratio were all heterogeneous, random effects model was used, and a summary receiver operating characteristic curve was generated. The area under the curve was 0.9445 for recurrent versus nonrecurrent ovarian cancer.
CONCLUSIONS: Positron emission tomography/computed tomography is a useful tool for predicting the diagnosis and restaging of suspected recurrent ovarian carcinoma.

Entities:  

Mesh:

Year:  2013        PMID: 23502451     DOI: 10.1097/IGC.0b013e31828a183c

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  9 in total

Review 1.  An update on the role of PET/CT and PET/MRI in ovarian cancer.

Authors:  Benjapa Khiewvan; Drew A Torigian; Sahra Emamzadehfard; Koosha Paydary; Ali Salavati; Sina Houshmand; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-08       Impact factor: 9.236

2.  Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.

Authors:  Federico Caobelli; Pierpaolo Alongi; Laura Evangelista; Maria Picchio; Giorgio Saladini; Marco Rensi; Onelio Geatti; Angelo Castello; Iashar Laghai; Cristina E Popescu; Carlotta Dolci; Cinzia Crivellaro; Silvia Seghezzi; Margarita Kirienko; Vincenzo De Biasi; Fabrizio Cocciolillo; Natale Quartuccio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-18       Impact factor: 9.236

3.  Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer.

Authors:  Yasuhiko Ebina; Hidemichi Watari; Masanori Kaneuchi; Mahito Takeda; Masayoshi Hosaka; Masataka Kudo; Hideto Yamada; Noriaki Sakuragi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-13       Impact factor: 9.236

4.  The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.

Authors:  Scott W Malm; Neale T Hanke; Alexander Gill; Liliana Carbajal; Amanda F Baker
Journal:  J Exp Clin Cancer Res       Date:  2015-04-01

5.  FDG PET/CT in cancer: comparison of actual use with literature-based recommendations.

Authors:  Henrik Petersen; Paw Christian Holdgaard; Poul Henning Madsen; Lene Meldgaard Knudsen; Dorte Gad; Anders Eggert Gravergaard; Max Rohde; Christian Godballe; Bodil Elisabeth Engelmann; Karsten Bech; Dorte Teilmann-Jørgensen; Ole Mogensen; Jens Karstoft; Jørgen Johansen; Janne Buck Christensen; Allan Johansen; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-30       Impact factor: 9.236

6.  Early-Stage Mucinous Ovarian Adenocarcinoma with Extensive Clotting in a Previously Healthy Young Female Patient: An Uncommon Presentation of a Relatively Uncommon Disease.

Authors:  Suchin R Khanna; Brave Nguyen; Mahmoud Charif
Journal:  Am J Case Rep       Date:  2017-06-15

Review 7.  Systematic Review on the Accuracy of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging in the Management of Ovarian Cancer: Is Functional Information Really Needed?

Authors:  Subapriya Suppiah; Wing Liong Chang; Hasyma Abu Hassan; Chalermrat Kaewput; Andi Anggeriana Andi Asri; Fathinul Fikri Ahmad Saad; Abdul Jalil Nordin; Sobhan Vinjamuri
Journal:  World J Nucl Med       Date:  2017 Jul-Sep

8.  Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.

Authors:  Young Jae Lee; Yong Man Kim; Phill Seung Jung; Jong Jin Lee; Jeong Kon Kim; Young Tak Kim; Joo Hyun Nam
Journal:  J Gynecol Oncol       Date:  2018-02-01       Impact factor: 4.401

9.  Habitat radiomics analysis of pet/ct imaging in high-grade serous ovarian cancer: Application to Ki-67 status and progression-free survival.

Authors:  Xinghao Wang; Chen Xu; Marcin Grzegorzek; Hongzan Sun
Journal:  Front Physiol       Date:  2022-08-25       Impact factor: 4.755

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.